-

04:57:23 PM

AMPH Stock News

AMPH - Amphastar Pharmaceuticals Inc

09/02/22 6:00 AM

Nasdaq : AMPH

conferences

Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sales and Marketing and Tony Marrs Sr. Vice President of Regulatory Affairs and Clinical Operations,

RHEA-AI

neutral

08/16/22 6:00 AM

Nasdaq : AMPH

fda approval

Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application ("NDA") for Epinephrine injection USP, 1 mg/10mL (0.1 mg/mL) Single Dose Pre-Filled

RHEA-AI

very positive

08/01/22 6:05 AM

Nasdaq : AMPH

earnings

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2022 ended June 30, 2022, after the market closes on Monday, August 8, 2022, and will hold a conference call to discuss its

RHEA-AI

neutral

07/19/22 6:00 AM

Nasdaq : AMPH

fda approval

Amphastar Receives FDA Approval for Vasopressin

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Vasopressin injection, USP 20 Units/mL, 1mL Single Dose Vial. In

RHEA-AI

neutral

06/06/22 6:05 AM

Nasdaq : AMPH

conferences

Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate Communications, will be presenting at the Jefferies Healthcare Conference on June 8, 2022 at 8:00 am Eastern

RHEA-AI

neutral

05/24/22 6:00 AM

Nasdaq : AMPH

fda approval

Amphastar Receives FDA Approval for Regadenoson

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Regadenoson injection, 0.08 mg/mL, 5mL Single Dose Pre-Filled

RHEA-AI

positive

05/09/22 4:05 PM

Nasdaq : AMPH

earnings

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2022. First Quarter Highlights

RHEA-AI

neutral

05/02/22 4:05 PM

Nasdaq : AMPH

earnings

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2022 ended March 31, 2022, after the market closes on Monday, May 9 th 2022, and will hold a conference call to discuss its

RHEA-AI

neutral

04/08/22 6:00 AM

Nasdaq : AMPH

fda approval

Amphastar Receives FDA Approval for Ganirelix Acetate Injection

Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ganirelix Acetate Injection, 250mg/0.5mL in a prefilled syringe.

RHEA-AI

very positive

04/06/22 4:10 PM

Nasdaq : AMPH

conferences

Amphastar Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive

RHEA-AI

neutral

AMPH Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.amphastar.com
CeoJack Zhang
Security nameAmphastar Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees1980
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address11570 6th St
StateCalifornia
CityRancho Cucamonga
Zip91730-6025
CountryUS
Phone19099809484

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.